S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
Log in

NYSE:PKI - PerkinElmer Stock Price, Forecast & News

$94.31
-0.06 (-0.06 %)
(As of 12/11/2019 04:00 PM ET)
Today's Range
$93.84
Now: $94.31
$94.48
50-Day Range
$84.09
MA: $89.61
$94.30
52-Week Range
$71.83
Now: $94.31
$103.00
Volume320,000 shs
Average Volume704,137 shs
Market Capitalization$10.48 billion
P/E Ratio26.12
Dividend Yield0.30%
Beta1.3
PerkinElmer, Inc provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services. Read More…

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorComputer and Technology
CUSIP71404610
Phone781-663-6900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.78 billion
Cash Flow$5.46 per share
Book Value$23.24 per share

Profitability

Net Income$237.93 million

Miscellaneous

Employees12,500
Market Cap$10.48 billion
Next Earnings Date1/30/2020 (Estimated)
OptionableOptionable

Receive PKI News and Ratings via Email

Sign-up to receive the latest news and ratings for PKI and its competitors with MarketBeat's FREE daily newsletter.


PerkinElmer (NYSE:PKI) Frequently Asked Questions

What is PerkinElmer's stock symbol?

PerkinElmer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PKI."

How often does PerkinElmer pay dividends? What is the dividend yield for PerkinElmer?

PerkinElmer declared a quarterly dividend on Thursday, October 24th. Shareholders of record on Friday, January 17th will be paid a dividend of $0.07 per share on Friday, February 7th. This represents a $0.28 dividend on an annualized basis and a yield of 0.30%. The ex-dividend date of this dividend is Thursday, January 16th. View PerkinElmer's Dividend History.

How were PerkinElmer's earnings last quarter?

PerkinElmer, Inc. (NYSE:PKI) issued its quarterly earnings data on Wednesday, October, 30th. The medical research company reported $1.06 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $1.01 by $0.05. The medical research company earned $706.92 million during the quarter, compared to analyst estimates of $722.69 million. PerkinElmer had a return on equity of 16.45% and a net margin of 8.27%. The company's revenue was up 4.8% on a year-over-year basis. During the same quarter last year, the firm earned $0.90 EPS. View PerkinElmer's Earnings History.

When is PerkinElmer's next earnings date?

PerkinElmer is scheduled to release their next quarterly earnings announcement on Thursday, January 30th 2020. View Earnings Estimates for PerkinElmer.

What guidance has PerkinElmer issued on next quarter's earnings?

PerkinElmer issued an update on its FY19 earnings guidance on Wednesday, October, 30th. The company provided earnings per share guidance of $4.07 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.03.

What price target have analysts set for PKI?

13 analysts have issued 1 year price objectives for PerkinElmer's stock. Their forecasts range from $41.00 to $115.00. On average, they anticipate PerkinElmer's share price to reach $75.65 in the next twelve months. This suggests that the stock has a possible downside of 19.8%. View Analyst Price Targets for PerkinElmer.

What is the consensus analysts' recommendation for PerkinElmer?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PerkinElmer in the last year. There are currently 9 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for PerkinElmer.

Has PerkinElmer been receiving favorable news coverage?

Headlines about PKI stock have been trending somewhat negative on Wednesday, according to InfoTrie. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. PerkinElmer earned a news impact score of -1.1 on InfoTrie's scale. They also assigned media stories about the medical research company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for PerkinElmer.

Are investors shorting PerkinElmer?

PerkinElmer saw a increase in short interest during the month of October. As of October 15th, there was short interest totalling 5,660,000 shares, an increase of 11.6% from the September 15th total of 5,070,000 shares. Based on an average daily volume of 708,900 shares, the short-interest ratio is presently 8.0 days. Approximately 5.1% of the company's stock are short sold. View PerkinElmer's Current Options Chain.

Who are some of PerkinElmer's key competitors?

What other stocks do shareholders of PerkinElmer own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PerkinElmer investors own include Cisco Systems (CSCO), NVIDIA (NVDA), Thermo Fisher Scientific (TMO), Visa (V), salesforce.com (CRM), Adobe (ADBE), Illumina (ILMN), AbbVie (ABBV), Alibaba Group (BABA) and General Electric (GE).

Who are PerkinElmer's key executives?

PerkinElmer's management team includes the folowing people:
  • Mr. Robert F. Friel, Chairman & CEO (Age 63)
  • Dr. Prahlad R. Singh, Pres & COO (Age 54)
  • Mr. James M. Mock, Sr. VP & CFO (Age 42)
  • Mr. Joel S. Goldberg, Sr. VP of Admin., Gen. Counsel & Sec. (Age 50)
  • Mr. James Corbett, Exec. VP and Pres of Discovery & Analytical Solutions (Age 56)

Who are PerkinElmer's major shareholders?

PerkinElmer's stock is owned by many different of institutional and retail investors. Top institutional investors include Select Equity Group L.P. (6.43%), Massachusetts Financial Services Co. MA (4.01%), State Street Corp (3.90%), Pictet Asset Management Ltd. (2.08%), Sumitomo Mitsui Trust Holdings Inc. (0.52%) and Robecosam AG (0.45%). Company insiders that own PerkinElmer stock include Alexis P Michas, Andrew Okun, Daniel R Tereau, Deborah A Butters, Frank Anders Wilson, James Corbett, Joel S Goldberg, Nicholas A Lopardo, Pascale Witz, Patrick J Sullivan, Peter Barrett, Prahlad R Singh and Robert F Friel. View Institutional Ownership Trends for PerkinElmer.

Which institutional investors are selling PerkinElmer stock?

PKI stock was sold by a variety of institutional investors in the last quarter, including Pictet Asset Management Ltd., State of Michigan Retirement System, Icon Advisers Inc. Co., First Citizens Bank & Trust Co., Russell Investments Group Ltd., Great Lakes Advisors LLC, State Street Corp and SG Americas Securities LLC. Company insiders that have sold PerkinElmer company stock in the last year include Alexis P Michas, Andrew Okun, Daniel R Tereau, Deborah A Butters, Joel S Goldberg, Nicholas A Lopardo, Pascale Witz, Peter Barrett and Prahlad R Singh. View Insider Buying and Selling for PerkinElmer.

Which institutional investors are buying PerkinElmer stock?

PKI stock was bought by a variety of institutional investors in the last quarter, including Robecosam AG, Massachusetts Financial Services Co. MA, Select Equity Group L.P., First Trust Advisors LP, Assenagon Asset Management S.A., Sumitomo Mitsui Trust Holdings Inc., Vestor Capital LLC and Nikko Asset Management Americas Inc.. View Insider Buying and Selling for PerkinElmer.

How do I buy shares of PerkinElmer?

Shares of PKI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is PerkinElmer's stock price today?

One share of PKI stock can currently be purchased for approximately $94.31.

How big of a company is PerkinElmer?

PerkinElmer has a market capitalization of $10.48 billion and generates $2.78 billion in revenue each year. The medical research company earns $237.93 million in net income (profit) each year or $3.61 on an earnings per share basis. PerkinElmer employs 12,500 workers across the globe.View Additional Information About PerkinElmer.

What is PerkinElmer's official website?

The official website for PerkinElmer is http://www.perkinelmer.com/.

How can I contact PerkinElmer?

PerkinElmer's mailing address is 940 WINTER STREET, WALTHAM MA, 02451. The medical research company can be reached via phone at 781-663-6900 or via email at [email protected]


MarketBeat Community Rating for PerkinElmer (NYSE PKI)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  445 (Vote Outperform)
Underperform Votes:  461 (Vote Underperform)
Total Votes:  906
MarketBeat's community ratings are surveys of what our community members think about PerkinElmer and other stocks. Vote "Outperform" if you believe PKI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PKI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/11/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel